While the Overweight rating suggests that Barclays expects Sarepta Therapeutics to outperform the market, the lowering of the price target could indicate a reduced growth expectation. This could potentially lead to short-term uncertainty among investors, but the overall impact is likely to be neutral as the Overweight rating is maintained.